Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Indication: Low dose prophylaxis of pneumocystis jirovecii (Pneumocystis carinii) infections post-transplant
Disease category: Infection
Commissioning responsibility: CCG
PbR excluded: No


No regular routine monitoring will be required in primary care for the first 3 years of treatment. Patient monitoring will be carried out as part of tertiary care services at least monthly for the first year and every 6–12 weeks in year 2 post-transplant. For the limited number of patients still using prophylactic co-trimoxazole after 2 years post-transplant monitoring will be carried out in tertiary care services every 3–4 months in year 3.

Prophylactic co-trimoxazole treatment would not be expected to continue beyond 3 years for most patients. Where patients require prophylactic co-trimoxazole in years 4 and 5 post-transplant, consultants should liaise with primary care clinicians to ensure suitable blood monitoring arrangements are requested.


LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:


Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG